How much does Ensifentrine cost in China?

Ohtuvayre (Ensifentrine)-Ensifentine Inhalation Suspension is a new and innovative inhaled treatment drug, mainly developed for patients with chronic obstructive pulmonary disease (COPD). Its biggest feature is that it has two mechanisms at the same time: as a dual inhibitor of phosphodiesterase3 (PDE3) and phosphodiesterase 4 (PDE4), it has dual effects of bronchodilation and anti-inflammatory, which can not only quickly relieve airway obstruction, but also reduce chronic inflammatory reactions in the lungs. Compared with traditional single-mechanism bronchodilators, exefentine has a more comprehensive effect in stabilizing symptoms, reducing cough and sputum volume, and improving lung function. It is especially suitable for long-term maintenance treatment of patients with moderate to severe COPD.

Currently, exefantine has been approved for marketing in the United States for twice-daily oral inhalation administration. Its commercial dosage form is atomized inhalation liquid with a specification of 3mg/2.5mL. Each box contains 60 doses, which is suitable for patients to use once in the morning and evening. Because it uses a standard jet atomization device for administration, it is relatively easy to operate and is also suitable for patients with limited lung function or elderly patients.

However, in the Chinese market, exefantine has not yet received marketing approval from the National Medical Products Administration (NMPA), so it cannot be purchased in domestic hospitals or pharmacies, and it is not included in the medical insurance directory. Currently, if domestic patients want to use the drug, they need to import it from overseas through legal cross-border drug purchase platforms or medical channels. According to overseas drug sales data, a box of the U.S. version of the original version of Exefantine costs more than 40,000 yuan. The specific price will be affected by the U.S. dollar exchange rate and regional differences.

Because this drug is still an innovative orphan drug, there are no generic drugs on the market in China, and market competition is limited, so the price remains high. With the continuous advancement of global clinical research and the gradual opening up of China's rare disease and chronic disease policies, ensefentin is expected to be included in the review channel for imported new drugs in the future and become a new option for domestic respiratory treatment.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html